SILO PHARMA INC (SILO)
US82711P2011 - Common Stock
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo’s SP-26 currently in development utilizes ketamine as primary therapeutic agent
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo’s SP-26 currently in development utilizes ketamine as primary therapeutic agent...
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma,...
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March ...
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024...
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment ...
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical...
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE...
Silo Pharma files for $25M mixed securities shelf (NASDAQ:SILO)
Silo Pharma files prospectus for the sale of $25 million mixed securities shelf in an update financial report. Not an offer to sell.
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo”...
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo...